Vietnam’s Vipdervir for Covid-19 treatment successfully synthesized and approved to test on humans

Thứ Ba, 10/8/2021| 14:57

The Ministry of Health has just approved a clinical research protocol for Vipdervir to treat Covid-19, from the Vietnamese medicinal herbs.

At an online press conference announcing the research results for Covid-19 treatment Tuesday, the Ministry of Health decided to approve the clinical research protocol for Vipdervir, a treatment from Vietnamese medicinal herbs, for Covid-19 patients, who are being treated at the Central Hospital for Tropical Diseases.

The project was chaired by Assoc. Prof. Dr. Le Quang Huan, a senior researcher of the Institute of Biotechnology, Academy of Science and Technology.

Vipdervir is prepared on the basis of a synergistic interaction between the active ingredients by the mechanism of preventing the adhesion of the virus to the host cell. Therefore, it will inactivate the virus in the host cell and inhibit the ability of the virus to multiply in the cell.

This means that viral particles entering the host cell will also lose their ability to proliferate and activate immune cells so that they recognize, blockade and eliminate viral particles.


Vietnam’s Vipdervir for Covid-19 treatment successfully synthesized and approved to test on humans

Vipdervir products. (Photo by the research team)

Tests on rabbits showed that Vipdervir was safe, immune-boosting, and inhibited the growth of H5N1 and SARS-CoV-2 viruses. Rabbits in the test were healthy, gained weight, and showed no abnormalities in internal organs.

The evaluation results also show that Vipdervir is able to inhibit the growth of SARS-CoV-2 at viral concentrations with positive test results (F0).

 According to Assoc. Prof. Dr. Le Quang Huan, the results of preclinical studies prove that Vipdervir has the safety and ability to inhibit the SARS-CoV-2 virus. This is also the basis for the team to continue to study its effectiveness on Covid-19 patients at the clinical stage.

Vipdervir needs further testing and research to evaluate its effectiveness before mass use. The research team also wishes to shorten the clinical trial period so that the drug can be put into use soon in the current special conditions.

Dr. Nguyen Ngo Quang, Deputy Director of the Department of Science, Technology and Training, hopes that Vipdervir proves its effects in clinical studies. If this product is approved by related agencies, it can be considered for licensing by the end of the year.